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Abstract
Background: Mucopolysaccharidosis type II (MPS II, Hunter syndrome), is caused by a deficiency of iduronate-2-
sulfatase (IDS). Despite the therapeutic effect of intravenous enzyme replacement therapy (ERT), the central nervous
system (CNS) defects persist because the enzyme cannot cross the blood-brain barrier (BBB). There have been
several trials of direct infusion to the cerebrospinal space showing promising results; however, this approach may
have limitations in clinical situations such as CNS infection. The objective of this study was to improve the CNS
defect with systemic high-dose ERT.
Methods: Systemic ERT was performed using three doses (1, 5, and 10 mg/kg weekly) of IDS for three different
durations (1, 3, and 6 months) in IDS knock out (KO) mice of two age groups (2 months, 8 months). GAG measurement
in tissues, brain pathology, and behavioral assessment were analyzed.
Results: Brain IDS activities increased in parallel with the concentrations of IDS injected. The glycosaminoglycan (GAG)
level and histopathology in the brains of the young mice improved in a dose- and duration-dependent manner;
however, those were not improved in the old mice, even at higher doses of IDS. The spontaneous alternation behavior
was recovered in young KO mice treated with≥ 5 mg/kg IDS; however, no significant improvement was observed in
old KO mice.
Conclusions: These results suggest that high-dose ERT given to mice of earlier ages may play a role in preventing
GAG accumulation and preventing CNS damage in IDS KO mice. Therefore, ERT above the present standard dose,
starting in early childhood, could be a promising treatment regimen for reducing neurological impairment in
Hunter syndrome.
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Background
Mucopolysaccharidosis (MPS) type II, also known as
Hunter syndrome [OMIM 309900], is a rare, X-linked
lysosomal storage disorder. The estimated incidence of
MPS is 1 per 162,000 live births [1], and MPS II is the
most common type of MPS, accounting for 54.6 % of
documented cases in Korea [2]. The disease is caused by
a deficiency of iduronate-2-sulfatase (IDS) (EC 3.1.6.13),
which is involved in lysosomal glycosaminoglycan (GAG)
catabolism. Patients with MPS II show a broad spectrum
of symptoms, including dysmorphic facial features, hepa-
tosplenomegaly, skeletal deformities, joint stiffness, severe
retinal degeneration, and hearing impairment. Progressive
deterioration of the central nervous system (CNS) is ob-
served in the severe phenotype of MPS II.
The therapeutic effects of current enzyme replacement
therapy (ERT) for MPS II include improvements in joint
mobility, gait, and pulmonary and respiratory functions,
and reductions in liver and spleen volumes and urinary
GAG excretion [3–7]. However, current ERT using the
labeled dose (0.5 mg/kg weekly) does not yield any neuro-
cognitive improvement because it cannot pass the blood-
brain barrier (BBB). CNS degenerative changes in MPS II
are devastating and must be resolved to improve the qual-
ity of life in patients with severe forms of Hunter syn-
drome. Thus, it is imperative to develop efficient therapies
that treat the CNS symptoms of Hunter syndrome.
In our previous study, a pseudotyped recombinant
adeno-associated virus type 2/8 vector encoding the hu-
man IDS gene was administered intravenously to IDS
knockout (KO) mice. This experiment involved liver-
specific gene therapy and indicated the effectiveness of
systemic high-dose therapy because the high level of en-
zyme expression in the liver induced a high level of en-
zymes in the blood [8].
Few studies using high-dose ERT have been conducted
using the KO mouse model of Hunter syndrome with
different study designs [9, 10]. Polito et al. [9] demon-
strated that systemic ERT allowed IDS to reach the brain
and, thus, to correct substantially the CNS pathology of
MPS II mice and to improve their neurobehavioral fea-
tures. However, GAG levels in the brain were not ana-
lyzed in their study. Our group previously suggested that
early, high-dose ERT attenuated ventriculomegaly and
histological abnormalities in the brains of IDS KO mice.
However, neurobehavioral assessment or IDS activity
analysis was not performed, and mice at a single age
(4 weeks) were only included in that study [10].
In the present study, systemic high-dose ERT was in-
vestigated in an IDS KO mouse model at different start-
ing ages and ERT doses and durations. This study
demonstrates that the systemic administration of human
IDS to young IDS KO mice enables the enzyme to de-
crease the GAG accumulated in the brain, correct many
neurodegeneration markers, and alleviate the neurobe-
havioral CNS disease phenotype.
Methods
Animals
All animal experiments were performed with the approval
of the Institutional Animal Care and Use Committee at
the Laboratory Animal Research Center, Samsung Bio-
medical Research Institute (Seoul, Korea). A previously re-
ported IDS KO mouse model [8] was used for the MPS II
animal model. Briefly, the KO mice were prepared by re-
placing exons 2 and 3 of the IDS gene with the neomycin
resistance gene. Carrier females were bred with male mice
with a B6/129 background strain to produce heteroge-
neous females, hemizygous male KO mice, wild-type
(WT) males, and female littermates. The genotypes of all
mice were confirmed via polymerase chain reaction using
DNA obtained from a tail snip. The C57BL6 strain was
used for the WT control mice. All animals in this study
were male.
Idursulfase beta
For ERT, recombinant human IDS beta (Hunterase®,
Green Cross Corp., Yongin, Korea) was used and adminis-
tered to the IDS-ERT group by intravenous injection. The
idursulfase beta treatment is well tolerated in Korean pa-
tients with MPS II and results in significantly reduced
urinary GAG excretion and improved 6-min walk test re-
sults in 0.5 mg/kg and 1 mg/kg weekly treatment groups
[11]. Hunterase® was concentrated by centrifugation in
Amicon Ultra Centrifugal Filters (Millipore, Bedford, MA,
USA) to a final concentration of 4.75 mg/mL. The prepa-
rations were diluted in 100 μL phosphate-buffered saline.
Different doses of Hunterase® were injected weekly over a
10–15-s period into the lateral tail vein of the mice, and
an equal volume of normal saline was injected in an iden-
tical manner into the WTand KO control groups.
Study design
The study protocol is shown in Table 1. Because the
mouse BBB is known to be maturated at 6 weeks old [12],
we used 8-week-old mice in the young mouse group.
Group A (short-term-treated young mouse group): A
group of young IDS KO mice (aged 2 months; n = 28;
seven mice per group) received Hunterase® at doses of
10, 5, or 1 mg/kg, or 1 mg/kg with 25 % mannitol
(0.1 ml) pretreatment via the tail vein weekly for
1 month. Because mannitol has been shown to facilitate
the entry of peripherally delivered therapeutic substances
to the CNS by disrupt the BBB transiently [13], the man-
nitol pretreatment group was added.
Group B (long-term-treated young mouse group): A
group of young IDS KO mice (aged 2 months; n = 35;
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seven mice per group) received Hunterase® at doses of 10
or 5 mg/kg or 5 mg/kg with 25 % mannitol (0.1 ml) pre-
treatment via the tail vein weekly for a total period of
6 months. In addition, two dose-change subgroups were
added (10 mg/kg for the first 2 months, then 5 or 2 mg/kg
for the subsequent 4 months).
Group C (mid-term treated old mouse group): A
group of old IDS KO mice (aged 8 months; n = 21; seven
mice per group) received Hunterase® at doses of 1, 5, or
10 mg/kg (0.1 ml) via the tail vein weekly for 3 months.
Age-matched IDS KO (n = 5) and WT (n = 5) mice
were used as controls for each group. The WT and IDS
KO control groups were injected weekly with normal sa-
line for the same period. After treatment, the animals
were sacrificed via an intraperitoneal injection of Zoletil
(50 mg/kg) and xylazine (10 mg/kg). Transcardiac perfu-
sion was performed with ice-cold 0.9 % saline, and har-
vested tissues were stored at −80 °C until biochemical
analysis was conducted.
Preparation of tissue extracts for the analysis of GAG
levels and quantitative analysis of GAG accumulation
Tissue extracts were prepared by homogenizing tissues
in phosphate-buffered saline (PBS) using a tissue
homogenizer. After hemisection in the midsagittal plane
of brain, the half of whole brain was assessed for GAG
levels and another half of whole brain was assessed for
pathology. Homogenates were centrifuged at 20 000 × g
for 30 min, and supernatants were collected. The total
protein concentration (mg/ml) was assayed with a
bicinchoninic acid (BCA) assay (Pierce, Rockford, IL,
USA). GAG concentrations in tissue homogenates and
urine were quantified using a colorimetric assay (Kamiya
Biomedical Co., USA) according to the manufacturer’s
instructions, and absorbance was measured at 620 nm
using a chondroitin 6-sulfate standard curve. The GAG
levels in tissue extracts were adjusted based on the total
protein concentration, which was measured with the
BCA assay, and are expressed as μg GAG per mg pro-
tein. GAG levels in urine were normalized to the cre-
atinine content.
IDS enzyme activity assay
The homogenates from the brains were obtained after
perfusion of saline. The IDS assay was performed as pre-
viously described [14]. IDS activity was measured in ho-
mogenates from the brains of treated mice (10 weeks of
age) at 4 h after a single injection with doses of 1, 5, or
10 mg/kg (each dose, n = 3). To perform a valid com-
parison of the specific enzyme activity, three individual
batches were analyzed. The enzyme activity was mea-
sured by determining the rate of enzyme-catalyzed hy-
drolysis of a synthetic substrate, 4-methylumbelliferyl-α-
L-iduronide-2-sulfate-Na2 (MU-αIdoA-2S), in 50 mM of
sodium acetate and 500 μg/mL bovine serum albumin at
pH 5.5. The total protein concentration was measured
with a BCA assay kit (Pierce, Rockford, IL, USA). The
released 4-methylumbelliferyl (4MU) was quantified by
Table 1 Study protocol
Group (start age) Subgroup Dose (mg/kg) Weekly infusion Duration (mo) Assessment Age (mo)
A (2 mo) n = 7 10 4 times 1 Tissue GAGs 3
Brain pathology 3n = 7 5
n = 7 1 Footprint analysis 3
n = 7 1 +mannitol
KO n = 5 Saline
WT n = 5 Saline
B (2 mo) n = 7 10 24 times 6 Tissue GAGs 8
Brain pathology 8n = 7 5
n = 7 5 +mannitol Footprint analysis 8
n = 7 10 (2mo)→ 5 (4mo)
n = 7 10 (2mo)→ 2 (4mo) Y-maze analysis 8
KO n = 5 Saline
WT n = 5 Saline
C (8 mo) n = 7 10 12 times 3 Tissue GAGs 11
n = 7 5 Brain pathology 11
n = 7 1 Footprint analysis 11
KO n = 5 Saline Y-maze analysis 11
WT n = 5 Saline
KO knockout, WT wild type, mo month(s)
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measuring the fluorescence (excitation 355 nm, emission
460 nm, Victor X4, PerkinElmer, Waltham, MA) against
a 4MU standard curve.
Histological analyses
After the perfusion of the mice with ice-cold normal sa-
line, their tissues were collected and fixed with 4 % para-
formaldehyde overnight at 4 °C. The next day, the
tissues were embedded in paraffin (Sigma0Aldrich, St
Louis, MO, USA) after dehydration through a 70–100 %
ethanol gradient. Finally, the paraffin blocks were cut to a
thickness of 4 μm. Lysosomal-associated membrane
protein-2 (Lamp-2) immunoreactivity is a lysosomal pro-
tein marker used for the detection of lysosomal storage dis-
orders. For the immunohistochemical detection of Lamp-
2, sections were treated with 10 % normal goat serum
(Dako, Carpinteria, CA) for 20 min at room temperature
to block nonspecific binding. Subsequently, sections were
incubated with rat anti-Lamp-2 monoclonal antibody (1/
100; Santa Cruz Biotechnology, Santa Cruz, CA) for
30 min at room temperature. After washing in PBS, the
sections were incubated for 30 min at room temperature
with HRP-labeled, polymer-conjugated secondary anti-
bodies against rat IgG (Lamp-2). A color reaction was
developed using ready-to-use 3,30-diaminobenzidine
substrate-chromogen solution (Dako, Carpinteria, CA) for
5 min followed by washing with distilled water. Finally,
the nuclei were lightly counter-stained with Mayer’s
hematoxylin for 1 min. The hematoxylin-eosin staining of
sections was performed according to standard protocols.
Images of each section were captured with a magni-
fier digital camera using a Nikon ECLIPS 80i FL Up-
right Microscope (Nikon, Melville, NY) and were
saved as JPEG files.
Footprint pattern analysis
Footprint pattern analysis was performed as previously de-
scribed in all groups to assess motor coordination [15, 16].
The mice were assessed at 3, 8 and 11 months in group A,
B and C, respectively, before being sacrificed after their
last injection. Gait abnormalities were assessed by painting
the paws of the mice with non-toxic, washable paint and
then placing the mice in a corridor lined with white paper.
The forepaws were dipped in red ink, and the hindpaws
were dipped in blue ink. All mice were trained for 3 days
to walk across a white sheet of paper without stopping.
The mice were assessed before being sacrificed after their
last injection. Both the treated and control mice were
tested during the same sessions to minimize variation.
Spontaneous alternation behavior assessed by the
Y-maze test
As another behavioral test, a Y-maze test was performed
to assess spatial working memory in groups B and C. The
Y-maze test has been reported to be useful for measuring
short-term memory, general locomotor activity, and
stereotypical behavior patterns [17–20]. The spontaneous
alternation behavior Y-maze test uses a horizontal maze
(30 cm long and 5 cm wide, with 12-cm-high walls) with
three arms (labeled A, B, and C). The maze floor and walls
are constructed of dark gray, polyvinyl plastic. Mice are
initially placed within one arm, and the number of alterna-
tions (i.e., consecutive entry sequences of ABC, CAB, or
BCA but not BAB) and the number of arm entries were
manually recorded for each mouse over a 5-min period.
The percentage of alternations was calculated according to
the following equation: Percentage alternation = [(Number
of alternations)/(Total arm entries-2)] × 100. The number
of arm entries per trial was used as an indicator of loco-
motor activity.
Statistical analysis
All results are expressed as the mean ± standard devi-
ation. Statistical significance was determined for the
compared measurements via one-way analysis of vari-
ance (ANOVA) tests, followed by Bonferroni’s correc-
tion. P-values <0.05 were considered significant. Stata
software (ver. 11.0, Stata Corp LP, College Station, TX,
USA) was used for all analyses.
Results
During ERT, all animals in this study were alive and
displayed no significant changes in behavior or vital
signs. There were no significant differences in body
weight or food consumption between the groups dur-
ing the study, and no treatment-related adverse events
were identified.
Footprint pattern analysis
The walking footprint patterns of all mice at the end of
the experiment are illustrated (Fig. 1a, b and c). Most
WT mice walked in a straight line away from the investi-
gator. By contrast, the IDS KO mice had an impaired
walking pattern. Their gait was slow, and they tended to
walk in an unstable manner with a short-stepped gait
characterized by strides of approximately half the length
of those of WT mice; furthermore, they did not walk in
a straight line in the tunnel, and their anterior and pos-
terior paw prints did not overlap. The KO mice treated
with any dose showed a trend towards amelioration of
these abnormalities in all groups [A (Fig. 1a), B (Fig. 1b),
and C (Fig. 1c)]. Each treatment group, even the KO
mice treated with 1 mg/kg in groups A and C, showed
an improved walking pattern; upon closer inspection,
the mice treated with 5 mg/kg or 10 mg/kg showed
slightly longer strides than the KO mice treated with
1 mg/kg in group C.
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Spontaneous alternation behavior assessed by the
Y-maze test
The spontaneous alternation behavior percentage (SAP)
of groups B and C are presented in Fig. 1d and e. In
group B, the KO group had significantly decreased SAP
compared with the WT group (Fig. 2a, p < 0.05). This be-
havior was recovered in the KO mice treated with
10 mg/kg, 5 mg/kg, or 5 mg/kg plus mannitol
Fig. 1 The walking footprint patterns of all of the mice at the end of the experiment. The walking footprint patterns show the forepaws (red) and
hindpaws (blue) of each mouse of groups A (a), B (b), and C (c). Most WT mice walked in a straight line away from the investigator. By contrast,
the IDS KO mice had an impaired walking pattern; their gait was slow, and they tended to walk in an unstable manner, with a short-stepped gait
of approximately half the stride length of WT mice. The KO mice treated with any dose of IDS showed a trend towards amelioration of these
abnormalities in all groups
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pretreatment (p < 0.05) without significantly changing
the number of arm entries. The number of arm entries
for KO mice was significantly decreased compared with
that of the WT mice (p < 0.05). The two dose-change
groups showed a trend of improving spontaneous alter-
nation behavior; however, these changes were not statis-
tically significant. In group C, the KO group displayed
significantly decreased SAP compared with the WT
group (Fig. 2b, p < 0.05). None of the treated mice in
group C showed a significant improvement of SAP.
GAG accumulation in brain tissue
The measured GAG concentrations in the brain tissues
of each group are presented in Fig. 3. In group A, the
brain tissues of the untreated KO mice group showed
significantly increased GAG concentrations compared
with those of the WT mice (p < 0.05). No significant dif-
ference in brain GAG levels was observed between the
IDS KO mice and the IDS KO mice treated with a dose
lower than 10 ng/kg. However, the IDS KO mice treated
with 10 mg/kg had significantly reduced brain GAG
levels compared with the IDS KO mice (p < 0.05)
(Fig. 3a). In group B, the brain tissues of the untreated
KO mice group showed significantly increased GAG
concentrations compared with the WT mice (p < 0.05).
All treated groups with different doses showed signifi-
cantly decreased brain GAG concentrations (p < 0.05)
compared with the untreated KO mice (Fig. 3b). Even
the 5 mg/kg group and the dose-change groups showed
some reduction of brain GAG levels when ERT was started
at a young age (2 months), after a 6-month treatment
period. In group C, the mid-term-treated old mouse group,
the brain tissues of the untreated KO mice group showed
significantly increased GAG concentrations compared with
the WT mice (p < 0.05). No significant change of
brain GAG levels was found in any of the treated
groups at any dose (Fig. 3c). IDS replacement therapy,
even with as high of a dose as 10 mg/kg, did not re-
duce brain GAG levels if treatment was initiated at
an old age (8 months).
Fig. 2 Effects of ERT on the spontaneous alternation behavior Y-maze test in groups B and C. In (a) and (b), the left picture shows the percentage
of spontaneous alternations, and the right picture shows the number of entries. In group B, the KO group significantly decreased their spontaneous
alternation behavior compared with the WT group (a, p < 0.05). This behavior was recovered in the KO mice treated with 10 mg/kg, 5 mg/kg, or 5
mg/kg plus mannitol pretreatment (p < 0.05) without significantly changing the number of arm entries. The number of arm entries by KO mice was
significantly decreased compared with that by the WT mice (p < 0.05). The two dose-change groups showed a trend towards improved spontaneous
alternation behavior; however, these changes were not statistically significant. In group C, the KO group significantly decreased their spontaneous
alternation behavior compared with the WT group (b, p < 0.05). No treated mice of group C showed any significant improvement of spontaneous
alternation behavior
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GAG accumulation in the other tissues and in urine
Accumulated GAG was markedly cleared from visceral
tissues such as the liver and kidney of all treated mice in
all groups. Accumulated GAG was markedly cleared in
the urine of all treated mice in group A (Additional file 1:
Figure S1).
IDS enzyme activity assay
The brain IDS activity was extremely high in the WT
mice, and brain IDS activities increased in parallel with
the concentrations of IDS injected in the KO mice
(Fig. 3d) (p < 0.05). Even in the IDS KO mice treated
with the lowest IDS dose (1 mg/kg), the IDS activities
measured in the brains were higher than those of the
untreated IDS KO mice.
Immunohistochemical analysis of brain tissue with Lamp-
2
Figure 4a, b and c displays the representative brain
histological features of the cerebral cortex, thalamus,
and cerebellum stained with Lamp-2 for each group. In
group A, the untreated KO mice showed increased anti-
Lamp-2 immunostaining, which marks lysosomal stor-
age, compared with the WT mice. No treatment group,
even the IDS KO mice treated with a 10 mg/kg dose,
showed reduced anti-Lamp-2 immunostaining (Fig. 4a).
In group B, Lamp-2 immunostaining was evident in all
areas of the untreated KO mice. Lamp-2 deposition was
more remarkable in the untreated KO mice of group B
(8 months) than that of group A (3 months). A definite
reduction in Lamp-2 immunostaining was observed in
all groups treated with 5 mg/kg, with 5 mg/kg plus
mannitol pretreatment, and with 10 mg/kg. The two
dose-change groups did not reveal any change in Lamp-
2 immunostaining (Fig. 4b). In group C, the area of
Lamp-2 immunostaining was smaller in the untreated
MPS II mice compared with that of the untreated KO
mice of group B. This can be explained by decreased
Lamp-2 deposits due to the decreased neuronal density
in the older KO mice of group C. There was no signi-
ficant reduction of Lamp-2 immunostaining in any
treatment group (Fig. 4c).
Fig. 3 Measurement of total GAG and IDS activity in the brain. In all groups, the brain tissues of untreated KO mice showed significantly increased
GAG concentrations compared with those of WT mice (p < 0.05). In group A, the IDS KO mice treated with 10 mg/kg IDS had significantly reduced
brain GAG levels compared with the untreated IDS KO mice (p < 0.05) (a). In group B, compared with the untreated KO mice group, all treated groups
showed significantly decreased brain GAG concentrations (p < 0.05) (b). In group C, no significant changes in brain GAG levels were found in any of
the treated groups at any dose when treatment was started later (at 8 months) (c). IDS activity was measured in homogenates from the brains of
treated mice (10 weeks of age) at 4 h after a single injection with doses of 1, 5, or 10 mg/kg (each dose, n= 3) (d). Brain IDS activities increased in parallel
with the concentrations of IDS injected in the IDS KO mice. The data are the mean ± standard deviations. p < 0.05 versus untreated IDS KO control
(ANOVA test). (***p< 0.001, **p < 0.01)
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Fig. 4 (See legend on next page.)
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Hematoxylin and eosin staining of brain tissue
Figure 4d, e and f displays representative brain histology
of the cerebral cortex, thalamus, and cerebellum stained
with hematoxylin and eosin for each group. In group A,
after 4 weeks of ERT, the reduction of vacuolation in the
cerebral cortex, thalamus, and cerebellar cortex was not
remarkable for all treatment group, even in the KO mice
treated with 10 mg/kg IDS (Fig. 4d). In group B, the un-
treated KO mice (8 months) had substantial widespread
cellular storage vacuoles presenting in the perivascular
cells and neurons in the cerebral cortex, thalamus, and
cerebellar cortex, which were more severe than in the
untreated KO mice of group A (3 months). In group B,
after 24 weeks of high-dose ERT (≥5 mg/kg weekly), the
brain tissue of the KO mice showed reduced vacuolation
in the cerebral cortex, thalamus, and cerebellar cortex
(Fig. 4e), which was not remarkable in the two dose-
change groups. In group C, after 12 weeks of ERT, the
brain tissues of the treated KO mice did not show a re-
duction of vacuolation in the cerebral cortex, thalamus,
or cerebellar cortex (Fig. 4f ).
Discussion
This study was designed to explore systemic ERT regi-
mens and identify the optimal dosage, time of ERT initi-
ation, and treatment period to protect the brain from
degeneration using IDS KO mice. Results show that the
early initiation and maintenance of systemic high-dose
ERT can ameliorate brain tissue damage and prevent the
progression of CNS defects.
In 2-month-old IDS KO mice, pathologic brain lesions
were clearly observed. A systemically infused weekly high-
dose (10 mg/kg) of IDS for 1 month was effective at re-
solving the accumulation of brain GAG; however, it was
not markedly effective at improving brain histopathology.
This could be explained by 1 month being too short a
period to resolve brain histopathology. Using a high-dose
IDS for 6 months (≥5 mg/kg weekly) brought about not
only decrease of brain GAG accumulation but also ameli-
oration of pathology of cerebral cortex, thalamus and
cerebellar cortex. In contrast to the high-dose-treated
group (5 and 10 mg/kg/week), the dose-transition group
(10 to 5 and 10 to 2 mg/kg/week) showed less prominent
amelioration of brain histopathology. This finding sug-
gests that high-dose ERT for a certain time (over
4 months) is required to maintain the improvement of
brain pathology. The mannitol pretreatment for disrupting
BBB did not show any remarkable difference. Mannitol
has been known to desrupt BBB transiently, however, it
might not be enough for large molecule such as IDS en-
zyme to pass the BBB.
In 8-month-old mice, high-dose ERT did not decrease
the brain GAG levels nor ameliorate brain histopath-
ology. However, accumulated GAG was completely
cleared from visceral tissues such as the liver and kidney
in all treated mice. The initiation of treatment in old
mice did not improve the CNS pathology because the
neurodegeneration was too advanced. Polito et al. de-
scribed that even a relatively low dose of IDS with both
short and prolonged treatment times ameliorated the
CNS defects in young IDS KO mice and that a high-
dose of IDS ameliorated the CNS defects in old IDS KO
mice [9]. Therefore, our observations are opposed to
those of Polito et al. in terms of the age that ERT should
be started and the dose/duration of ERT required for
neuroprotection. Above all, our study analyzed brain
GAG levels as the end product as well as brain path-
ology to provide comprehensive evidences of the action
of the enzyme passing through the BBB.
In this study, the brain IDS activities in IDS-treated KO
mice were higher than those of the untreated IDS KO
mice; however, the IDS activities in IDS-treated KO mice
were much lower compared with those measured in the
WT mice. These results correspond with those of a previ-
ous study [9] and suggest that a small amount of enzyme
in brain can improve the CNS pathology of IDS KO mice.
Systemic high-dose ERT also showed improvement in
behavioral tests evaluating motor coordination and
short-term memory. The IDS KO mice had an impaired
walking pattern, which can be caused by limitation of
joint motion or poor coordination. The KO mice treated
with any dose of IDS showed a trend towards
(See figure on previous page.)
Fig. 4 Histology of brain tissues such as the cerebral cortex, thalamus, and cerebellum with anti-Lamp-2 and H&E (200X). In group A, the untreated KO
mice showed increased anti-Lamp-2 immunostaining compared with the WT mice. No treatment group showed reduced anti-Lamp-2 immunostaining
(a). In group B, Lamp-2 immunostaining was evident in all areas of the untreated KO mice. A definite reduction in Lamp-2 immunostaining was observed
in all treated groups at 5 mg/kg, 5 mg/kg plus mannitol pretreatment, or 10 mg/kg. The two dose-change groups did not reveal remarkable change in
Lamp-2 immunostaining (b). In group C, the area of Lamp-2 immunostaining was less massive in the untreated MPS II mice compared with that of the
untreated KO mice of group B. There was no significant reduction of Lamp-2 immunostaining in any treatment group (c). The number of distinct and
enhanced neuronal vacuolation (arrow) in perivascular cells and neurons was markedly increased in the untreated KO groups of groups A, B, and C.
Dyslamination and decreased cellular density were noted in the cortical area of the untreated KO groups. In group A, the reduced vacuolation was not
remarkable in all treatment groups, even in the KO mice treated with 10 mg/kg after 4 weeks of ERT (d). In group B, the degree of vacuolation was more
severe than in the untreated KO mice of group A. After 24 weeks of high-dose ERT (5 mg/kg/week or higher), the brain tissues of the KO mice showed a
reduced degree of vacuolation, which was not remarkable in the two dose-change groups (e). In group C, the brain tissues of the treated KO mice did
not show reduced vacuolation after 12 weeks of ERT (f)
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amelioration of these abnormalities in all groups. These
results can be explained by both the improvement of joint
motion and the decrease of accumulated GAG in the
brain. The improvement of walking pattern in old IDS KO
mice may rather be due to systemic effects of ERT on the
muscles and joints as well as improved coordination.
Spontaneous alternation behavior was analyzed with the
Y-maze test for groups B and C. The untreated KO mice
showed significantly decreased alternation behavior, as
previously reported [16]. However, in the present study,
the number of arm entries was decreased in the untreated
KO mice compared with the WT mice, in contrast to the
previous report [16]. This finding suggests that the KO
mice may have poor physical activity due to characteristics
such as joint contracture and their tendency to hesitate.
Spontaneous alternation behavior was recovered in young
KO mice treated with 5 mg/kg or higher IDS; however, no
significant improvement was observed in old KO mice,
even those treated with 10 mg/kg of IDS.
At present, how IDS crosses the BBB to reach the brain
remains unknown. There has been increasing evidence
that when high serum levels of lysosomal enzymes are
achieved through either gene therapy or ERT, a small frac-
tion of the enzyme is able to cross the BBB [21–23]. First,
one possible mechanism that may contribute to the trans-
cytosis of these water–soluble proteins is pinocytosis [24].
Second, injection-dependent hydrodynamic effects due to
rapid enzyme infusion in IDS KO mice cannot be ex-
cluded. However, this is less likely because only ~100 μL
of volume was administered by tail-vein injection in the
present study. Third, the extracellular pathway that has
been shown to allow small quantities of molecules as large
as albumin to cross the BBB represents a possible mech-
anism [25]. Finally, it is possible that residual mannose-6-
phosphate receptor or other uncharacterized receptors
more efficiently facilitate the transport of IDS in the con-
text of high plasma enzyme levels. Further studies ad-
dressing the mechanism of crossing the BBB will perhaps
be important for modifying the IDS enzyme to promote
increased uptake into the brain. We also suggest that a
next generation form of IDS with enhanced activity should
be developed to improve CNS defects.
There was no administration-related hypersensitivity re-
sponses with high-dose ERT in the MPS II mice. For ap-
plying to humans, there are several possible adverse
effects to be considered, including the immediate immune
reaction such as hypersensitivity reactions or production
of circulating antibodies. Preparing for the hypersensitivity
reaction and monitoring the antibodies levels will assure
optimal treatment. In addition, the cost of high-dose ERT
will be very high; therefore, determining the optimal dose
and interval should be considered to minimize the cost in
a following study. In order to provide early treatment
to patients with Hunter syndrome, early diagnosis is
most important. Newborn screening of Hunter syn-
drome, therefore, should be considered.
In the present study, the low IDS level in brain could
decrease of brain GAG level, which suggests high-dose
intermittent treatment could be possible. This study is
meaningful in terms of the potential clinical application
of these findings to improve CNS problems of Hunter
syndrome. Although intraventricular [16] and intrathecal
[26, 27] enzyme or gene vector administration [8, 28]
have produced neurological improvements, these strat-
egies are limited by their invasive nature. Intrathecal en-
zyme administration to patients is particularly difficult
due to poor patient cooperation or to device dysfunc-
tion. Intraventricular administration can bypass the BBB;
however, the systemic effects of this technique remain in
question, and it requires specialized neurosurgical skills.
In one Japanese study [29], hematopoietic stem cell
transplantation (HSCT) in patients with Hunter syn-
drome showed effectiveness towards brain involvement,
when performed before signs of brain atrophy appear.
However, the disadvantages of HSCT are the mortality
and morbidity associated with the transplantation pro-
cedure and difficulty of finding of suitable donors.
Several systemic high-dose ERT researches have been
conducted in other lysosomal disease animal models.
Most studies [9, 23, 30–36] showed reduced neuropath-
ology, however, one study [37] did not. Overall, the inef-
ficiency of the CNS delivery in normal-dose ERT may be
circumvented by high-dose ERT.
Conclusions
In conclusion, the early application of high-dose ERT
may play a role in preventing GAG accumulation, thus
reducing ensuing brain damage in MPS II mice. There-
fore, it is suggested that ERT above the current standard
dose started as early as possible could be a promising
treatment regimen for reducing neurological impairment
by preventing brain GAG accumulation in patients with
severe Hunter syndrome. The mannitol pretreatment
did not show any remarkable difference. Further study
to identify the ideal IDS dose and protocol to sufficiently
treat the CNS phenotype of MPSII mice is required.
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